Royal Bank Of Canada Spero Therapeutics, Inc. Transaction History

Royal Bank Of Canada

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.27 - $1.8 $2,487 - $3,526	1,959 New	1,959 $2,000
Q4 2023 Feb 14, 2024	BUY	$1.0 - $1.47 $15 - $22	15 Added 5.0%	315 $0
Q3 2023 Nov 14, 2023	BUY	$1.2 - $1.63 $360 - $488	300 New	300 $0
Q3 2022 Nov 14, 2022	BUY	$0.68 - $2.2 $29 - $94	43 New	43 $0
Q2 2022 Aug 15, 2022	SELL	$0.74 - $7.44 $145,111 - $1.46 Million	-196,097 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$7.87 - $15.15 $106,260 - $204,555	13,502 Added 7.39%	196,097 $1.71 Million
Q4 2021 Feb 14, 2022	BUY	$13.09 - $18.77 $32,633 - $46,793	2,493 Added 1.38%	182,595 $2.92 Million
Q3 2021 Nov 15, 2021	BUY	$13.03 - $19.51 $2.32 Million - $3.47 Million	177,945 Added 8249.65%	180,102 $3.32 Million
Q2 2021 Aug 16, 2021	BUY	$12.22 - $15.79 $26,358 - $34,059	2,157 New	2,157 $30,000

13.9M

200

200

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $41.4M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.